<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The FDA is delaying its decision to authorize Moderna Inc’s (NASDAQ: MRNA) COVID-19 vaccine for adolescents to assess the risk of a rare inflammatory heart condition, Wall Street Journal reported citing people familiar with the matter. The agency has been inspecting the risk of myocarditis among younger men vaccinated with Moderna’s shot, especially versus Pfizer Inc (NYSE: PFE) and BioNTech SE’s (NASDAQ: BNTX) vaccine.
...read full article on Benzinga
